The demand for endometriosis treatment in Japan is expected to reach USD 273.5 billion by 2035, reflecting an absolute increase of USD 89.6 billion over the forecast period. Starting at USD 183.9 billion in 2025, the demand is expected to grow at a steady CAGR of 4.1%. This growth is driven by an increasing awareness of the condition, improvements in diagnostic capabilities, and the growing number of women seeking effective treatments for endometriosis.
Endometriosis is a medical condition in which tissue similar to the uterine lining grows outside the uterus, causing chronic pain, fertility issues, and other complications. As the condition becomes more widely recognized and diagnosed, the demand for medical treatments, including pharmaceuticals, surgeries, and alternative therapies, is expected to increase. Innovations in treatments, particularly those focused on non-invasive and personalized options, will continue to drive growth in this sector.
Japan's aging population and the growing focus on women's health contribute to the rising demand for treatments for chronic conditions like endometriosis. The Japanese healthcare system's growing commitment to advancing treatments and improving patient care will also support this industry's expansion.
Between 2025 and 2030, the demand will grow from USD 183.9 billion to USD 191.3 billion, adding USD 7.4 billion. This period accounts for 8.3% of the total forecasted growth over the decade. During this phase, the growth will be driven primarily by the increasing awareness of endometriosis among both healthcare professionals and the general public. Improved diagnostic tools and greater recognition of the condition’s symptoms will result in earlier diagnoses, leading to better treatment outcomes. The demand for pharmaceutical treatments will increase as more women are diagnosed and seek medical solutions to manage pain and other symptoms associated with endometriosis.
The late growth phase from 2030 to 2035 will see the demand accelerate significantly, rising from USD 191.3 billion to USD 273.5 billion, adding USD 82.2 billion. This phase contributes 91.7% to the total growth. The sharp acceleration during this period will be driven by several factors, including significant advancements in treatment options, such as more personalized therapies, novel pharmaceutical products, and minimally invasive surgical approaches. As the condition is better understood and treated with greater precision, a surge in demand will occur. Increased access to healthcare and stronger advocacy for women's health will contribute to greater utilization of available treatments.
| Metric | Value |
|---|---|
| Japan Endometriosis Treatment Sales Value (2025) | USD 183.9 billion |
| Japan Endometriosis Treatment Forecast Value (2035) | USD 273.5 billion |
| Japan Endometriosis Treatment Forecast CAGR (2025 2035) | 4.1% |
Demand for endometriosis treatment in Japan is rising as awareness grows and more women of reproductive age seek effective care for a condition often under‑recognized. Improved understanding of endometriosis an inflammatory condition affecting tissue outside the uterus that can cause pain and fertility challenges is leading to earlier diagnosis and greater treatment uptake. This shift is supported by enhanced screening practices and greater specialist access.
Advancements in therapeutic options and surgical techniques are fueling the trend. New hormone‑based treatments and minimally invasive procedures allow for better symptom management and fertility preservation, priorities for many patients and clinicians. These developments are helping women receive more tailored and effective care, further driving treatment demand.
Evolving healthcare policies, expanded insurance coverage, and increased funding for women’s health are also contributing. As treatment pathways become more integrated into standard gynecological care, access improves and treatment volumes rise. With Japan’s aging population and strong healthcare infrastructure further enabling uptake, demand for endometriosis treatment is projected to increase steadily through 2035.
Demand is segmented by drug type, treatment type, and distribution channel. By drug type, demand is divided into oral contraceptives, progestins, NSAIDs, GnRH analogues, and LNR-IUDs. In terms of treatment type, demand is categorized into hormonal therapy and pain management. The industry is also segmented by distribution channel, including hospital pharmacies, e-commerce, retail pharmacies, and drug stores. Regionally, demand is divided into Kanto, Kinki, Chubu, Kyushu & Okinawa, Tohoku, and the Rest of Japan.
Oral contraceptives account for 46% of the demand for endometriosis treatment in Japan. They are commonly used to regulate the menstrual cycle and reduce the symptoms of endometriosis, including pain and inflammation. Oral contraceptives work by suppressing ovulation and reducing the growth of endometrial tissue, helping manage the condition effectively.
The demand for oral contraceptives is driven by their widespread use as a first-line treatment for endometriosis. They are a non-invasive, accessible, and affordable option for many patients, making them highly preferred. Oral contraceptives are often recommended due to their ability to not only alleviate symptoms but also improve quality of life by providing long-term symptom relief. As more women are diagnosed with endometriosis and seek effective treatment options, the demand for oral contraceptives is expected to remain strong in Japan, particularly for those seeking an easy-to-administer, cost-effective solution.
Hormonal therapy accounts for 75% of the demand for endometriosis treatment in Japan. Hormonal therapies are highly effective in managing the symptoms of endometriosis by regulating hormone levels that influence the growth of endometrial tissue. These therapies, which include oral contraceptives, progestins, and GnRH analogues, are the cornerstone of treatment for many women suffering from this condition.
The high demand for hormonal therapy is driven by its proven ability to reduce pain, prevent further growth of endometrial lesions, and improve fertility outcomes for patients. As hormonal therapy targets the underlying hormonal imbalances in endometriosis, it remains the most effective option for long-term symptom control and disease management. As awareness of endometriosis increases and more women are diagnosed and seek treatment, hormonal therapy continues to be the most widely recommended and utilized form of treatment in Japan, reinforcing its dominance in the industry.
Hospital pharmacies account for 45% of the demand for endometriosis treatment in Japan. Hospital pharmacies are the primary point of access for patients seeking treatment for complex conditions like endometriosis. These pharmacies often provide specialized medications, including hormonal therapies and other prescriptions tailored to individual needs. The role of hospital pharmacies is crucial because they provide expert advice and closely monitor the treatment progress of patients undergoing long-term therapy.
As the diagnosis and management of endometriosis require close medical supervision, hospital pharmacies are the preferred distribution channel for many patients. Hospitals offer access to a range of specialized treatments, ensuring patients receive the most appropriate and up-to-date therapies. As the healthcare system in Japan continues to prioritize comprehensive care, particularly for conditions like endometriosis, hospital pharmacies remain a central hub for delivering these essential medications, contributing to their continued dominance in the distribution of endometriosis treatments.
Endometriosis Treatments are being adopted in obstetrics‑gynecology settings for pain relief, infertility support and long‑term management. Key drivers include the high prevalence of the condition in women of reproductive age, government and professional guidelines promoting earlier diagnosis and treatment, and patient demand for less invasive and more personalized options. Restraints include the persistent diagnostic delay, the high cost of newer therapies, and limited insurance or reimbursement coverage for some advanced treatments.
In Japan, demand is growing because the recognition of endometriosis’ impact on quality of life, fertility and productivity is rising. More Japanese women seek care as pelvic pain, dysmenorrhea and infertility are increasingly seen as signals not to be ignored. Clinical practice guidelines from Japanese professional societies support earlier intervention and a wider range of therapies, which drives treatment uptake. Moreover, the trend towards minimally invasive surgery and novel medical therapies encourages patients and physicians to pursue treatment earlier, expanding the addressable population and boosting demand for endometriosis care services.
Innovations are supporting growth in Japan by offering new treatment options and improving outcomes. Advances include extended‑regimen hormonal therapies (e.g., combined oral contraceptives tailored for endometriosis‑associated pain) shown to improve quality of life in Japanese women. Research into non‑hormonal treatments and better diagnostic tools is also underway, increasing hope for broader treatment options. These innovations help overcome limitations of older therapies, appeal to women desiring less invasive care, and support incorporation of personalized medicine approaches thus enhancing demand for advanced treatment across clinics and hospitals in Japan.
Despite favourable trends, several barriers limit the full adoption of endometriosis treatments in Japan. A major challenge is the diagnostic delay, where women often experience symptoms for years before receiving proper diagnosis and care, which can reduce the effectiveness of early interventions. Cost and reimbursement issues present another barrier: newer therapies may be expensive and not fully covered, limiting access. Clinical inertia and patient awareness gaps persist some women and providers may attribute symptoms to "normal" menstruation and delay treatment. Evidence gaps and comfort with older regimens may slow uptake of newer treatments even when available.
| Region | CAGR (%) |
|---|---|
| Kyushu & Okinawa | 5.1% |
| Kanto | 4.7% |
| Kinki | 4.1% |
| Chubu | 3.6% |
| Tohoku | 3.2% |
| Rest of Japan | 3.0% |
The demand for endometriosis treatment in Japan is growing across all regions, with Kyushu & Okinawa leading at a 5.1% CAGR. This growth is driven by increased awareness, early diagnosis, and the adoption of advanced treatment methods. Kanto follows with a 4.7% CAGR, supported by the region's strong healthcare infrastructure and large population. Kinki shows a 4.1% CAGR, influenced by its presence of specialized medical centers. Chubu, with a 3.6% CAGR, sees steady adoption due to improvements in healthcare services. Tohoku and the Rest of Japan experience moderate growth at 3.2% and 3.0%, respectively, supported by ongoing investments in women's health.
Kyushu & Okinawa is experiencing the highest demand growth for endometriosis treatment in Japan, with a 5.1% CAGR. The region’s growth is attributed to increased awareness of endometriosis and early diagnosis, along with a focus on improving healthcare services in the region. Kyushu, including cities like Fukuoka, is seeing greater investments in women’s health services, including specialized treatment options for endometriosis.
The regional healthcare system is becoming more equipped with advanced technologies for treating conditions like endometriosis, which helps in providing better care and treatment outcomes for patients. Moreover, Okinawa’s population, which has historically had limited access to specialized care, is benefiting from improved healthcare infrastructure. Government initiatives to improve medical access and support for women's health have contributed significantly to this growth. As awareness of endometriosis continues to rise, demand for treatments in Kyushu & Okinawa is expected to remain strong.
Kanto is experiencing steady demand for endometriosis treatment, with a 4.7% CAGR. The region benefits from a well-established healthcare system and advanced medical infrastructure, particularly in Tokyo. Kanto's large population and concentration of specialized medical centers ensure that women have better access to diagnostic services and treatment options for endometriosis.
The demand for endometriosis treatment in Kanto is driven by the region’s leading role in healthcare research and technology, allowing for early detection and improved therapeutic approaches. High awareness levels among both healthcare professionals and the general public, coupled with increasing support from advocacy groups and medical institutions, are further fueling the growth of endometriosis treatments in this region. As Kanto remains a healthcare innovation hub, the demand for effective endometriosis care is expected to grow steadily.
Kinki is experiencing steady growth in demand for endometriosis treatment, with a 4.1% CAGR. The region, which includes Osaka and Kyoto, has a strong presence of specialized medical centers and hospitals, contributing to the adoption of advanced treatments for endometriosis. The focus on improving women's health services in this region is driving greater access to treatments, including surgical interventions and hormone therapies.
The region's well-established healthcare system and medical research institutions are also facilitating the development and use of advanced diagnostic tools and treatment options. With growing awareness of the condition and an increasing number of women seeking early diagnosis and treatment, Kinki is expected to see continued demand for endometriosis treatments. The steady expansion of specialized healthcare facilities will further support the region’s growth in this area.
Chubu is seeing moderate growth in the demand for endometriosis treatment, with a 3.6% CAGR. The region’s healthcare sector is expanding, with increased availability of specialized treatment centers and a rising focus on women’s reproductive health. Cities like Nagoya are benefiting from improved access to diagnostic services and medical professionals trained in the latest endometriosis treatment techniques.
Chubu’s growth is influenced by greater public awareness of endometriosis and the availability of advanced medical technologies for diagnosis and treatment. The region’s ongoing commitment to improving healthcare access and services for women is contributing to the steady demand for endometriosis treatments. As more healthcare providers in Chubu embrace comprehensive care for women with endometriosis, the region is expected to experience continued growth in treatment demand.
Tohoku is experiencing moderate demand growth for endometriosis treatment, with a 3.2% CAGR. The region's growth is driven by ongoing improvements in healthcare infrastructure and an increasing focus on women’s reproductive health. Tohoku has seen a rise in specialized treatment centers and clinics that offer advanced care for endometriosis patients. As the region continues to improve access to diagnostic services and treatment options, more women are seeking care for this condition.
Government initiatives aimed at improving healthcare services and access to specialized treatment in Tohoku are also contributing to the growth in demand for endometriosis treatment. While Tohoku may not be as central to Japan’s healthcare industry as other regions, its growing focus on reproductive health, combined with a more accessible healthcare system, ensures that demand for endometriosis care will continue to rise in the coming years.
The Rest of Japan is experiencing moderate growth in the demand for endometriosis treatment, with a 3.0% CAGR. While the region does not have the same level of healthcare infrastructure as Kanto or Kyushu & Okinawa, it is benefiting from national government initiatives to raise awareness about women’s health issues and improve access to specialized care for conditions like endometriosis.
In rural areas and smaller cities, there is increasing recognition of the importance of early diagnosis and comprehensive treatment options for endometriosis. As healthcare facilities improve and local practitioners become more educated on endometriosis management, more women in the Rest of Japan are able to access appropriate care. With continued government support and a growing awareness of the condition, demand for endometriosis treatment will likely continue to grow steadily in the Rest of Japan.
Demand for endometriosis treatments in Japan is rising steadily as awareness of the condition increases and access to gynecological care improves. With the country’s aging population and an increased focus on women’s health, more patients and healthcare providers are prioritizing effective management options for endometriosis which affects a significant proportion of women of reproductive age. Diagnostic improvements and healthcare system support further fuel uptake of available therapies and facilitate earlier intervention.
In the Japanese demand landscape, AbbVie Inc. holds an estimated 30.0% share, reflecting its strong presence in women’s health and its portfolio of therapies for endometriosis‑related pain and symptom management. Other major contributors include Bayer AG, AstraZeneca, Pfizer Inc., and Teva Pharmaceutical Industries Ltd., each offering hormone‑based treatments, pain relief options, and ongoing research into novel therapeutic approaches for endometriosis in Japan.
Drivers of demand in Japan include the growing recognition of endometriosis as a chronic condition, the drive to improve fertility outcomes, and increased adoption of treatment guidelines in gynecological practices. Additional factors include greater interest in non‑surgical options and improved patient support programs. Despite progress, barriers such as delayed diagnosis, treatment cost, and limited access in certain regions may moderate adoption. Nonetheless, the outlook for endometriosis treatment demand in Japan remains positive, supported by ongoing innovations and evolving patient needs.
| Items | Values |
|---|---|
| Quantitative Unit | USD 183.9 Billion |
| Drug Type | Oral Contraceptives, Progestins, NSAIDs, GnRH analogues, LNR-IUDs |
| Treatment Type | Hormonal Therapy, Pain Management |
| Distribution Segment | Hospital Pharmacies, E-Commerce, Retail Pharmacies, Drug Stores |
| Regions Covered | Kyushu & Okinawa, Kanto, Kinki, Chubu, Tohoku, Rest of Japan |
| Key Players Profiled | Takeda Pharmaceutical Company Limited, Kissei Pharmaceutical Co., Ltd., AbbVie Inc., Bayer AG, AstraZeneca plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd. |
| Additional Attributes | Dollar sales by drug type, treatment type, distribution channels, and regional demand are key contributors to the endometriosis treatment industry in Japan. The primary drug types include oral contraceptives, progestins, NSAIDs, GnRH analogues, and LNR-IUDs, with treatment types focused on hormonal therapy and pain management. Sales through hospital pharmacies, e-commerce, retail pharmacies, and drug stores are significant, with regions like Kanto, Kyushu & Okinawa, and Kinki leading the demand. |
The global demand for endometriosis treatment in japan is estimated to be valued at USD 183.9 billion in 2025.
The market size for the demand for endometriosis treatment in japan is projected to reach USD 273.5 billion by 2035.
The demand for endometriosis treatment in japan is expected to grow at a 4.1% CAGR between 2025 and 2035.
The key product types in demand for endometriosis treatment in japan are oral contraceptives, progestins, nsaids, gnrh analogues and lnr-iuds.
In terms of treatment type segment, hormonal therapy segment to command 75.0% share in the demand for endometriosis treatment in japan in 2025.
Our Research Products
The "Full Research Suite" delivers actionable market intel, deep dives on markets or technologies, so clients act faster, cut risk, and unlock growth.
The Leaderboard benchmarks and ranks top vendors, classifying them as Established Leaders, Leading Challengers, or Disruptors & Challengers.
Locates where complements amplify value and substitutes erode it, forecasting net impact by horizon
We deliver granular, decision-grade intel: market sizing, 5-year forecasts, pricing, adoption, usage, revenue, and operational KPIs—plus competitor tracking, regulation, and value chains—across 60 countries broadly.
Spot the shifts before they hit your P&L. We track inflection points, adoption curves, pricing moves, and ecosystem plays to show where demand is heading, why it is changing, and what to do next across high-growth markets and disruptive tech
Real-time reads of user behavior. We track shifting priorities, perceptions of today’s and next-gen services, and provider experience, then pace how fast tech moves from trial to adoption, blending buyer, consumer, and channel inputs with social signals (#WhySwitch, #UX).
Partner with our analyst team to build a custom report designed around your business priorities. From analysing market trends to assessing competitors or crafting bespoke datasets, we tailor insights to your needs.
Supplier Intelligence
Discovery & Profiling
Capacity & Footprint
Performance & Risk
Compliance & Governance
Commercial Readiness
Who Supplies Whom
Scorecards & Shortlists
Playbooks & Docs
Category Intelligence
Definition & Scope
Demand & Use Cases
Cost Drivers
Market Structure
Supply Chain Map
Trade & Policy
Operating Norms
Deliverables
Buyer Intelligence
Account Basics
Spend & Scope
Procurement Model
Vendor Requirements
Terms & Policies
Entry Strategy
Pain Points & Triggers
Outputs
Pricing Analysis
Benchmarks
Trends
Should-Cost
Indexation
Landed Cost
Commercial Terms
Deliverables
Brand Analysis
Positioning & Value Prop
Share & Presence
Customer Evidence
Go-to-Market
Digital & Reputation
Compliance & Trust
KPIs & Gaps
Outputs
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Demand Signal Repository Solutions Market Size and Share Forecast Outlook 2025 to 2035
Demand Side Management Market Size and Share Forecast Outlook 2025 to 2035
Demand Response Market Analysis - Size, Share, and Forecast Outlook 2025 to 2035
North America Shipping Supplies Market Trends – Innovations & Growth 2024-2034
Demand of Kozani Saffron in Greece Analysis - Size, Share & Forecast 2025 to 2035
Demand of No-acid Whey Strained Dairy Processing Concepts in European Union Size and Share Forecast Outlook 2025 to 2035
Demand for Bronte Pistachio in Italy Analysis - Size, Share & Forecast 2025 to 2035
Demand and Trend Analysis of Gaming Monitor in Western Europe Size and Share Forecast Outlook 2025 to 2035
Demand and Trend Analysis of Gaming Monitor in Korea Size and Share Forecast Outlook 2025 to 2035
Demand and Trend Analysis of Gaming Monitor in Japan Size and Share Forecast Outlook 2025 to 2035
Glycine Soja (Soybean) Seed Extract Market Size and Share Forecast Outlook 2025 to 2035
Demand and Trend Analysis of Yeast in Japan - Size, Share, and Forecast Outlook 2025 to 2035
Demand of Pistachio-based desserts & ingredients in France Analysis - Size, Share & Forecast 2025 to 2035
Western Europe Men’s Skincare Market Analysis – Forecast 2023-2033
Demand and Trends Analysis of Stevia in Japan Size and Share Forecast Outlook 2025 to 2035
Japan Women’s Intimate Care Market Trends – Growth & Forecast 2024-2034
Demand and Trend Analysis of Fabric Stain Remover in Korea Size and Share Forecast Outlook 2025 to 2035
Demand and Sales Analysis of Paper Cup in Korea Size and Share Forecast Outlook 2025 to 2035
Demand and Sales Analysis of Paper Cup in Western Europe Size and Share Forecast Outlook 2025 to 2035
Demand of MFGM-enriched Powders & RTDs in European Union Size and Share Forecast Outlook 2025 to 2035
Demand for Endometriosis Treatment in Japan
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
